CytomX Therapeutics Price to Sales Ratio 2014-2022 | CTMX
Historical PS ratio values for CytomX Therapeutics (CTMX) over the last 10 years. The current P/S ratio for CytomX Therapeutics as of March 23, 2023 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| CytomX Therapeutics P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2023-03-23 |
1.69 |
|
1.53 |
| 2022-09-30 |
1.45 |
$1.10 |
1.31 |
| 2022-06-30 |
1.83 |
$1.12 |
1.64 |
| 2022-03-31 |
2.67 |
$1.09 |
2.45 |
| 2021-12-31 |
4.33 |
$1.09 |
3.97 |
| 2021-09-30 |
5.09 |
$1.14 |
4.48 |
| 2021-06-30 |
6.33 |
$1.25 |
5.06 |
| 2021-03-31 |
7.73 |
$1.36 |
5.67 |
| 2020-12-31 |
6.55 |
$1.28 |
5.10 |
| 2020-09-30 |
6.65 |
$1.16 |
5.71 |
| 2020-06-30 |
8.33 |
$0.98 |
8.52 |
| 2019-12-31 |
8.31 |
$1.27 |
6.54 |
| 2019-09-30 |
7.38 |
$1.36 |
5.41 |
| 2019-06-30 |
11.22 |
$1.41 |
7.94 |
| 2019-03-31 |
10.75 |
$1.76 |
6.10 |
| 2018-12-31 |
15.10 |
$1.47 |
10.24 |
| 2018-09-30 |
18.50 |
$1.93 |
9.60 |
| 2018-06-30 |
22.86 |
$2.30 |
9.95 |
| 2018-03-31 |
28.45 |
$1.99 |
14.32 |
| 2017-12-31 |
21.11 |
$1.94 |
10.89 |
| 2017-09-30 |
18.17 |
$2.26 |
8.02 |
| 2017-06-30 |
15.50 |
$1.78 |
8.69 |
| 2017-03-31 |
17.27 |
$1.64 |
10.52 |
| 2020-03-31 |
7.67 |
$1.41 |
5.45 |
| 2016-12-31 |
10.99 |
$0.42 |
26.45 |
| 2016-09-30 |
15.68 |
$0.47 |
33.10 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.115B |
$0.070B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
